Elisha Fredman MD Profile
Elisha Fredman MD

@ElishaFredman

Followers
302
Following
147
Statuses
343

GU Radiation Oncology team lead, Director of research and innovation, Davidoff Cancer Center, Rabin Medical Center, (views are my own, posts not med advice)

Petah Tikvah, IL
Joined July 2022
Don't wanna be here? Send us removal request.
@ElishaFredman
Elisha Fredman MD
2 days
@DrAndrewLoblaw Very much agree. Cure rates are probably as good as they'll be, so how can we make the experience of treatment, and the weeks/months/years after as good as possible
0
0
1
@ElishaFredman
Elisha Fredman MD
2 days
@DrAndrewLoblaw @gerard_morton 100%. 1 vs 2 HDR has been asked and answered. What hasn't been fully flushed out is the exact mechanism and whether there is something unique about prostate RadBio that explains the apparent benefit of at least some fractionation
0
0
0
@ElishaFredman
Elisha Fredman MD
2 days
@_ShankarSiva @TheLancetOncol @DrAndrewLoblaw @WallisCJD @DrAlexLouie @MichaelStaehler @spsutkaMD @DrewMoghanaki @drphil_urology @wandering_gu @MRoupret @uretericbud Nice work! SBRT is a phenomenal option for these patients! Hope to have our data out soon for the larger tumors also 💪💪. Way to go Shankar
1
0
3
@ElishaFredman
Elisha Fredman MD
2 days
@VedangMurthy @akshay_dinesan @RadOncTMC @docpriyamvada @drmaneesh_singh @PrachiSMehta Great example of curiosity --> discovery!! And now we all benefit! Strong work 👍👍
1
2
5
@ElishaFredman
Elisha Fredman MD
3 days
RT @APCCC_Lugano: Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-a…
0
31
0
@ElishaFredman
Elisha Fredman MD
3 days
Way to go guys! I haven't kept track but what is this, like a paper a month?! 💪💪
@DrAndrewLoblaw
Dr. Andrew Loblaw
3 days
Kudos @cristian_udo for leading this analysis of long-term oncologic outcomes of 2 vs 5 fractions of SBRT. Stay tuned for HDR mono vs SBRT (#SHERBET) @ESTRO_RT 2025 Free link: @dr_vesi @alison_tree @HimanshuNagarMD @ElishaFredman doing RCTs of 2 vs 5fx
0
0
1
@ElishaFredman
Elisha Fredman MD
3 days
RT @DrAndrewLoblaw: Kudos @cristian_udo for leading this analysis of long-term oncologic outcomes of 2 vs 5 fractions of SBRT. Stay tuned…
0
8
0
@ElishaFredman
Elisha Fredman MD
7 days
@merino_tomas @VedangMurthy @DrAndrewLoblaw @DrSpratticus @aleberlin2 Agree mostly with Vedang 😊. He is young, healthy, I'm going to assume with very good baseline function and PS. Nowadays w/ option of highly effective and safe 5-fx pelvic RT, can most likely cure and prevent need for ADT in future. While aggressive, I would offer
0
0
6
@ElishaFredman
Elisha Fredman MD
11 days
@singhv2003 Very true. But a challenge, as many pts are older w/ multiple comorbidities, surgery not w/o risks, and even biopsy has high chance of bleed. Radiographic diagnosis is pretty good, but a worthwhile endeavor to keep working on
0
0
1
@ElishaFredman
Elisha Fredman MD
17 days
@dr_alimuhammad @DrAndrewLoblaw @AmarUKishan @alison_tree @_ShankarSiva I would, certainly 6mo, and if tolerating, cont. to 18mo. He technically has HR disease and LT-ADT shown to ⬆️ clinically meaningful endpoints. Depending on specs of the bx (# cores per ROI), the math could even work out to 50%➕. I'd lay off the LNs w/ RT, prob min/no benefit 👍
0
0
2
@ElishaFredman
Elisha Fredman MD
24 days
Next major game changer in Rad Onc - PULSAR, hands down. In my experience so far, decent/mixed results in metastatic RCC and 2 phenomenal outcomes in widely metastatic and progressing cutaneous melanoma. So much to yet learn and so much potential @BobTimmermanMD @DavidSherMD
0
4
20
@ElishaFredman
Elisha Fredman MD
24 days
Couldn't agree more! I'd say 80% of our men at the Davidoff Center, whether intermediate, high, or oligomet, are getting SBRT. It almost pains me to have to offer someone more than 5 (or 6) fxs! Let's keep heading toward efficient and effective care 👍👍 @RabinMedical_
@DrAndrewLoblaw
Dr. Andrew Loblaw
24 days
Together we will make #SBRT the #1 prostate treatment for men with prostate cancer. It’s already the #1 treatment @Sunnybrook And we’re only just beginning: 0mm real time motion management, DIL dose painting, MPD de-escalation, spacers, 2 fx, immobilization… it’s all coming!
1
0
5
@ElishaFredman
Elisha Fredman MD
25 days
RT @drdavidpalma: We are looking to feature research focused on: 1) Growing the evidence base for SBRT 2) Clinical implementation of SBRT…
0
7
0
@ElishaFredman
Elisha Fredman MD
1 month
RT @oncodaily: Prophylactic Pelvic RT with SBRT for High-Risk node negative Prostate Cancer - @gusviani @VedangM
0
4
0
@ElishaFredman
Elisha Fredman MD
1 month
That's exactly the goal. Fortunately we've gotten to the point where "cure" is achievable for almost all, so our focus needs to be on quality , safety, efficiency. Not worried about losing my job if "we cure cancer" b/c our job is part of the solution 👍👍.
@DrAndrewLoblaw
Dr. Andrew Loblaw
1 month
Agree 💯 @sandraturner49 We now cure 99% of men with localized prostate cancer (see Kennedy et al; ). The future is in preserving QOL. #SBRT lies at the heart of those gains, esp with tighter margins, adaptive RT, immobil’n, DIL dose painting + spacers
0
0
6
@ElishaFredman
Elisha Fredman MD
1 month
Important question is in the context of CSPC, do the benefits of NOT having to have ADT outweigh the ⬆️ risk of biochemical progression, at which time ADT can always be given. MDT w/ SBRT, followed by ADT if necessary may be preferred by many pts.
@DrAndrewLoblaw
Dr. Andrew Loblaw
1 month
Another critically important study on value of ADT + RT (vs RT or ADT alone) for men at high risk of recurrence. But why are we surprised? There are only like 300 RCTs showing the same effect in non-metastatic #ProstateCancer (it’s more like 20 but I like hyperbole‼️)
0
0
2
@ElishaFredman
Elisha Fredman MD
1 month
RT @VedangMurthy: With the new year, comes new insight. Is 25Gy/5# enough for prophylactic nodal RT in high-risk #ProstateCancer? Borrowed…
0
56
0
@ElishaFredman
Elisha Fredman MD
1 month
Very worthwhile expert opinion report on urethral sparing! My personal practice - planning MRI, contour urethra on T2 (usually requires 5-6mm brush), limit to 102% of rx, add 2mm PRV, limit that to 104%. Goal of maintaining coverage but keeping relatively cool 😎
@JennKa12
Jennifer Le Guévelou
1 month
💥 Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey
0
0
8
@ElishaFredman
Elisha Fredman MD
4 months
@nickva1 @TylerSbrt @DrAndrewLoblaw @jaydetsky @VedangMurthy @alison_tree @cpeedell @VickersBiostats Great background and overall I feel and practice very similarly
0
0
1
@ElishaFredman
Elisha Fredman MD
4 months
@SbrtSean I would do one at the beginning to confirm bladder and rectum, but then tracking (fiducial or MR) is ideal!
0
1
3